Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 26 12 2018
revised: 29 01 2019
accepted: 31 01 2019
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 28 5 2019
Statut: epublish

Résumé

Colistin is administered as its inactive prodrug colistimethate (CMS). Selection of an individualized CMS dose for each patient is difficult due to its narrow therapeutic window, especially in patients with chronic kidney disease (CKD). Our aim was to analyze CMS use in patients with CKD. Secondary objectives were to assess the safety and efficacy of CMS in this special population. In this prospective observational cohort study of CMS-treated CKD patients, CKD was defined as the presence of a glomerular filtration rate (GFR) < 60 mL/min/m² for more than 3 months. The administered doses of CMS were compared with those recently published in the literature. Worsened CKD at the end of treatment (EOT) was evaluated with the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria. Colistin plasma concentrations (C

Identifiants

pubmed: 30717123
pii: molecules24030530
doi: 10.3390/molecules24030530
pmc: PMC6384574
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
colistinmethanesulfonic acid DL2R53P963
Colistin Z67X93HJG1

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI132154
Pays : United States

Références

J Chromatogr B Biomed Sci Appl. 2001 Sep 25;761(2):167-75
pubmed: 11587346
Crit Care. 2003 Oct;7(5):R78-83
pubmed: 12974973
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
Int J Antimicrob Agents. 2005 Jan;25(1):11-25
pubmed: 15620821
Kidney Int. 2005 Jun;67(6):2089-100
pubmed: 15882252
J Antimicrob Chemother. 2006 Feb;57(2):306-11
pubmed: 16396919
Lancet Infect Dis. 2006 Sep;6(9):589-601
pubmed: 16931410
Clin Microbiol Infect. 2006 Dec;12(12):1227-30
pubmed: 17121631
Kidney Int. 2008 Mar;73(5):538-46
pubmed: 18160961
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6
pubmed: 19433570
Clin Infect Dis. 2009 Jun 15;48(12):1724-8
pubmed: 19438394
Int J Antimicrob Agents. 2010 Feb;35(2):194-9
pubmed: 20006471
Int J Antimicrob Agents. 2010 Mar;35(3):297-300
pubmed: 20045293
Antimicrob Agents Chemother. 2010 Oct;54(10):4503-5
pubmed: 20660694
J Infect. 2011 Feb;62(2):187-90
pubmed: 21129401
Antimicrob Agents Chemother. 2011 Jul;55(7):3284-94
pubmed: 21555763
Clin Infect Dis. 2011 Nov;53(9):879-84
pubmed: 21900484
Clin Microbiol Infect. 2012 Jan;18(1):30-9
pubmed: 21988234
Clin Infect Dis. 2012 Jun;54(12):1720-6
pubmed: 22423120
Int J Antimicrob Agents. 2013 Aug;42(2):178-81
pubmed: 23769664
BMC Infect Dis. 2013 Aug 19;13:380
pubmed: 23957376
Antimicrob Agents Chemother. 2014;58(1):440-6
pubmed: 24189256
Antimicrob Agents Chemother. 2014 Dec;58(12):7324-30
pubmed: 25267662
Lancet Infect Dis. 2015 Feb;15(2):225-34
pubmed: 25459221
J Antimicrob Chemother. 2015;70(6):1804-11
pubmed: 25698772
J Antimicrob Chemother. 2015 Dec;70(12):3291-7
pubmed: 26318190
Clin Infect Dis. 2016 Mar 1;62(5):552-558
pubmed: 26607424
Clin Infect Dis. 2016 Dec 23;64(5):565-571
pubmed: 28011614
BMC Infect Dis. 2017 Jan 5;17(1):11
pubmed: 28056821
Int J Antimicrob Agents. 2016 Dec;48(6):725-727
pubmed: 28128096
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559275
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28893780
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239

Auteurs

Luisa Sorli (L)

Infectious Diseases Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. lsorli@hospitaldelmar.cat.
Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. lsorli@hospitaldelmar.cat.

Sonia Luque (S)

Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. sluque@hospitaldelmar.cat.
Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. sluque@hospitaldelmar.cat.

Jian Li (J)

Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, 3800 Victoria, Australia. Jian.Li@monash.edu.

Eva Rodríguez (E)

Nephrology Department, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB). CEXS-Universitat Pompeu Fabra, 08003, 08003 Barcelona, Spain. ERodriguezG@parcdesalutmar.cat.

Nuria Campillo (N)

Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. FAR1207@parcdesalutmar.cat.
Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. FAR1207@parcdesalutmar.cat.

Xenia Fernandez (X)

Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. Xfernandez@parcdesalutmar.cat.
Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. Xfernandez@parcdesalutmar.cat.

Jade Soldado (J)

Infectious Diseases Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. 61762@parcdesalutmar.cat.
Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. 61762@parcdesalutmar.cat.

Ignacio Domingo (I)

Infectious Diseases Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. 62887@hospitaldelmar.cat.
Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. 62887@hospitaldelmar.cat.

Milagro Montero (M)

Infectious Diseases Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. 95422@parcdesalutmar.cat.
Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. 95422@parcdesalutmar.cat.

Santiago Grau (S)

Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. SGrau@hospitaldelmar.cat.
Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. SGrau@hospitaldelmar.cat.

Juan P Horcajada (JP)

Infectious Diseases Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, 08003 Barcelona, Spain. JHorcajada@hospitaldelmar.cat.
Spanish Network for Research in Infectious Diseases (REIPI RD 16/0016/0015), Instituto de Salud Carlos III, 28001 Madrid, Spain. JHorcajada@hospitaldelmar.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH